Post by DINAMIQS

Scaling AAV and LVV programs from process development to commercial manufacturing is one of the most demanding transitions in the viral vector space, and the margin for error narrows significantly at 1,000 L. Join CTO Eduard Ayuso and other experts from large pharma, CDMOs, and biotech in a webinar panel discussion to tackles the practical, commercial, and scientific challenges that determine whether scale-up succeeds or stalls. Register to attend: https://lnkd.in/eD_xnm8s